Information Provided By:
Fly News Breaks for November 19, 2015
PRTA
Nov 19, 2015 | 07:29 EDT
RBC Capital says that the data on Prothena's orphan amyloidosis drug continues to look strong, while regulators in Europe and the U.S. are becoming more favorably disposed to the treatment. RBC is upbeat on the company's new Parkinson's drug and expects positive data for the drug to be reported in 1H16. It views the stock as undervalued and keeps an Outperform rating on the shares.
News For PRTA From the Last 2 Days
There are no results for your query PRTA